Prospects of using biological products in vitiligo

Abstract

A literature review is presented regarding the vitiligo reaction to biological agents for treating this dermatosis itself and as a side effect of the treatment of other diseases. Notably, the results of therapy with biological products and the researchers’ opinions on this subject are ambiguous because of the positive evidence of repigmentation of vitiligo foci, as well as cases of vitiligo in patients who received biological products for the treatment of another pathology.

Keywords

vitiligo / vitiligo treatment / biological products / ustekinumab / adalimumab / infliximab / etanercept

References

[1] Nobelprize.org

[2] Zaragoza V., Perez A., Sanchez J.L., Oliver V., Martinez L., Alegre V. Long-term safety and efficacy of etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 2010; 101(1): 47-53.

[3] Alwawi E.A., Krulig E., Gordon K.B. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol.Ther. 2009; 22(5):431-40.

[4] Speeckaert R., Lambert J., van Geel N. Learning from success and failure: biologics for non-approved skin diseases. Front. Immunol. 2019; 10:1918. doi: 10.3389/fimmu.2019.01918.

[5] Elkady A., Bonomo L., Amir Y., Vekaria A.S., Guttman-Yassky E. Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata. JAAD Case Rep. 2017; 3(6): 477-9.

[6] Bae J.M., Kim M., Lee H.H., Kim K.J., Shin H., Ju H.J., Kim G.M., et al. Increased risk of vitiligo following anti-Tumor Necrosis Factor therapy: a 10-year population-based cohort study. J. Invest Dermatol. 2018; 138(4):768-74.

[7] Wakkee M., Assen Y.J., Thio H.B., Neumann M. Repigmentation of vitiligo during efalizumab. J. Am. Acad. Dermatol. 2008; 59(2):57-8.

[8] Rkman D., Likic R., Bebek M., Gnjidic M., Gamulin M. Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report. Croat Med. J. 2019; 60(6):552-5.

[9] Lolli C., Medri M., Ricci M., Schepisi G., Filograna A., Giorgi U.D., Stanganelli I. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. Medicine (Baltimore). 2018; 97(52):е13810.

[10] Uenami T., Hosono Y., Ishijima M., Kanazu M., Akazawa Y., Yano Y., et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. Lung Cancer. 2017; 109:42-4. doi: 10.1016/j.lungcan.2017.04.019.

[11] Nakamura Y., Tanaka R., Asami Y., Teramoto Y., Imamura T., Sato S., et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J. Dermatol. 2017; 44(2):117-22.

[12] Alghamdi K.M., Khurrum H., Taieb A., Ezzedine K. Treatment of generalized vitiligo anti-TNFα Agents. J. Drugs Dermatol. 2012; 11(4):534-9.

[13] Speeckaert R., Mylle S., van Geel N. IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res. 2019; 32(6):842-7.

RIGHTS & PERMISSIONS

Eco-Vector